Literature DB >> 11879332

The treatment of prostate cancer: an overview of current options.

G Pirtskhalaishvili1, R L Hrebinko, J B Nelson.   

Abstract

PURPOSE: The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease. OVERVIEW: With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer. CLINICAL IMPLICATIONS: The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11879332     DOI: 10.1046/j.1523-5394.2001.96009.x

Source DB:  PubMed          Journal:  Cancer Pract        ISSN: 1065-4704


  15 in total

Review 1.  Methods for volume assessment of prostate cancer.

Authors:  Heinz-Peter Schlemmer; Stefan Corvin
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

2.  System for MR image-guided prostate interventions: canine study.

Authors:  Robert C Susil; Axel Krieger; J Andrew Derbyshire; Attila Tanacs; Louis L Whitcomb; Gabor Fichtinger; Ergin Atalar
Journal:  Radiology       Date:  2003-09       Impact factor: 11.105

Review 3.  Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer.

Authors:  Vinay Prabhu; Ted Lee; Tyler R McClintock; Herbert Lepor
Journal:  Rev Urol       Date:  2013

4.  Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells.

Authors:  Bo Yin; Yang Yang; Zhiqiang Zhao; Yu Zeng; Steven M Mooney; Ming Li; Xuewen Xu; Yongsheng Song; Bin Wu; Zhibo Yang
Journal:  Int J Oncol       Date:  2011-01-11       Impact factor: 5.650

5.  Ligand-specific dynamics of the androgen receptor at its response element in living cells.

Authors:  Tove I Klokk; Piotr Kurys; Cem Elbi; Akhilesh K Nagaich; Anindya Hendarwanto; Thomas Slagsvold; Ching-Yi Chang; Gordon L Hager; Fahri Saatcioglu
Journal:  Mol Cell Biol       Date:  2006-12-22       Impact factor: 4.272

Review 6.  Inguinal hernia after radical retropubic prostatectomy: risk factors and prevention.

Authors:  Johan Stranne; Pär Lodding
Journal:  Nat Rev Urol       Date:  2011-04-05       Impact factor: 14.432

7.  3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study.

Authors:  Matthias P Lichy; Jörg Pintaske; Raimund Kottke; Jürgen Machann; Aristotelis Anastasiadis; Stefan Roell; Jörg Hennenlotter; Till Diergarten; Fritz Schick; Arnulf Stenzl; Claus D Claussen; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

8.  The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

Authors:  Yulan Sun; Daret K St Clair; Fang Fang; Graham W Warren; Vivek M Rangnekar; Peter A Crooks; William H St Clair
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

9.  Androgens transduce the G alphas-mediated activation of protein kinase A in prostate cells.

Authors:  Gargi Bagchi; Juanjuan Wu; John French; Jae Kim; Nader H Moniri; Yehia Daaka
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

10.  Novel expressed sequences identified in a model of androgen independent prostate cancer.

Authors:  Steven N Quayle; Heidi Hare; Allen D Delaney; Martin Hirst; Dorothy Hwang; Jacqueline E Schein; Steven J M Jones; Marco A Marra; Marianne D Sadar
Journal:  BMC Genomics       Date:  2007-01-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.